What is the prevalence of Pseudohyperaldosteronism?

Pseudohyperaldosteronism, also known as apparent mineralocorticoid excess, is a rare genetic disorder that affects the body's ability to regulate sodium and potassium levels. It is caused by mutations in the HSD11B2 gene, which encodes an enzyme called 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2). This enzyme is responsible for inactivating cortisol, a hormone that can bind to mineralocorticoid receptors and mimic the effects of aldosterone.

The prevalence of pseudohyperaldosteronism is not well-established due to its rarity and the lack of comprehensive population studies. However, it is estimated to affect approximately 1 in 50,000 to 100,000 individuals worldwide. The disorder can present in infancy or early childhood and may lead to symptoms such as hypertension, low potassium levels, metabolic alkalosis, and excessive urine production.

Early diagnosis and treatment are crucial to prevent complications associated with pseudohyperaldosteronism. Management typically involves the use of medications that block the effects of cortisol, such as glucocorticoid receptor antagonists. Additionally, dietary modifications may be necessary to maintain electrolyte balance.

Further research and awareness are needed to better understand the prevalence and impact of pseudohyperaldosteronism on affected individuals and their families.